 |
BioWorld-International-2005-08-17
NeuroSearch's Shares Plunge As NS2330 Fails In Three Trials
NeuroSearch's Shares Plunge As NS2330 Fails In Three Trials
NeuroSearch's shares crashed more than 40 percent Aug. 10 on news that its lead drug candidate, NS2330, failed to achieve efficacy in two Phase IIb trials for Parkinson's disease and a third Phase IIb trial for Alzheimer's disease, dashing hopes that the compound would move into Phase III. (BioWorld International)